Premium
Cisplatin‐based chemotherapy after retroperitoneal lymph node dissection in patients with pathological stage II nonseminomatous germ cell tumors
Author(s) -
Culine Stéphane,
Theodore Christine,
Farhat Fadi,
Bekradda Mohammed,
TerrierLacombe MarieJosée,
Droz JeanPierre
Publication year - 1996
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/(sici)1096-9098(199603)61:3<195::aid-jso6>3.0.co;2-6
Subject(s) - medicine , etoposide , cisplatin , retroperitoneal lymph node dissection , chemotherapy , testicular cancer , vinblastine , germ cell tumors , bleomycin , cyclophosphamide , urology , oncology , surgery
In order to assess the results of cisplatin‐based chemotherapy after primary lymph node dissection in patients with pathological stage II nonseminomatous germ cell tumors of the testis, we retrospectively reviewed the long‐term outcome of 44 patients who received adjuvant chemotherapy at Institut Gustave Roussy over a 7‐year period. Two chemotherapy regimens were sequentially delivered. Twenty‐three patients were treated with vinblastine, cyclophosphamide, bleomycin, actinomycin D, and cisplatin (mVAB‐6, four cycles), while 21 patients received a combination of etoposide and cisplatin (EP, four cycles). After a median follow‐up of 6 years, all patients remain free from progression. The long‐term toxicity included retrograde ejaculation in eight patients and severe ototoxicity in two patients. We conclude that four cycles of cisplatin‐based chemotherapy for pathological stage II testicular cancer resulted in a 100% cure rate with minimal toxicity. © 1996 Wiley‐Liss, Inc.